Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women [2]

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 6, 2002, Pages 1051-1052

  Lemaitre, Rozenn N ^a   Psaty, Bruce M ^a   Heckbert, Susan R ^a   Smith, Nicholas L ^a   Longstreth Jr , W T ^a   Rosendaal, Frits R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; LETTER; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; CLINICAL TRIALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; MUTATION; POSTMENOPAUSE; PROTHROMBIN; RISK FACTORS; WASHINGTON;

EID: 0036078385     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000019853.06725.5A     Document Type: Letter

References (4)

1. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
2. Estrogen after ischemic stroke: Effect of estrogen replacement on risk of recurrent stroke and death in the Women's Estrogen for Stroke Trial (WEST)
3. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women